Back
Insmed Incorporated (INSM)
BiotechnologyINSM · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$116.53
+3.27%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$-6.42
ROE
-294.5%
Gross margin
81.8%
Debt/Equity
1.05x
Revenue growth
229.6%
Insmed Incorporated — company intelligence
Earnings surprises
Q1 2026$-0.76 vs $-0.98 est+22.3%
Q4 2025$-1.54 vs $-1.32 est-17.0%
Q3 2025$-1.75 vs $-1.37 est-28.1%
Q2 2025$-1.70 vs $-1.32 est-28.9%
Analyst consensus · 29 analysts
28 Buy1 Hold0 Sell
Updated Jul 6, 2026
Insider activity · 90 days
8 buys36 sellsnet -124,833 shares
Lewis WilliamSell 1,292 · Jun 25, 2026
Lewis Williamother 12,518 · Jun 25, 2026
Lewis WilliamSell 12,091 · Jun 25, 2026
Recent SEC filings
4 — Insider transaction reportJul 8, 2026
4 — Insider transaction reportJun 26, 2026
4 — Insider transaction reportJun 24, 2026
Latest news
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory — Yahoo · 2w ago
Should Insmed’s (INSM) NASDAQ-100 Exit and TPIP Focus Require Action From Investors? — Yahoo · 2w ago
Is Insmed (INSM) One of the Most Promising Healthcare Stocks After Cantor Fitzgerald’s Target Raise? — Yahoo · 2w ago
Evercore ISI Group Maintains Outperform on Insmed, Lowers Price Target to $160 — Benzinga · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Insmed Incorporated
Weekly undervalued picks (like INSM)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.